FDA Approval Zenocutuzumab For NRG1 Fusion Cancers
Update: 2025-01-21
Description
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of zenocutuzumab for NSCLC with an NRG1 fusion. NRG1 fusions are rare but important events seen in many cancer types, including NSCLC. Zenocutuzumab is a HER2/HER3 bispecific antibody that showed clear efficacy in NSCLC and in pancreatic cancer that harbored an NRG1 fusion.
Guest: Dr. Alison Schram, Assistant Attending Physician and Section Head of Oral Therapeutics in Early Drug Development at Memorial Sloan Kettering Cancer Center in New York
Guest: Dr. Alison Schram, Assistant Attending Physician and Section Head of Oral Therapeutics in Early Drug Development at Memorial Sloan Kettering Cancer Center in New York
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
